

# Resource Summary Report

Generated by [ASWG](#) on Aug 27, 2026

## Psychoactive Drug Screening Program Ki Database

RRID:SCR\_003281

Type: Tool

### Proper Citation

Psychoactive Drug Screening Program Ki Database (RRID:SCR\_003281)

### Resource Information

**URL:** <http://pdsp.med.unc.edu/pdsp.php>

**Proper Citation:** Psychoactive Drug Screening Program Ki Database (RRID:SCR\_003281)

**Description:** THIS RESOURCE IS NO LONGER IN SERVICE. Documented on January 5, 2023. Database of information on the abilities of drugs to interact with an expanding number of molecular targets. It serves as a data warehouse for published and internally-derived Ki, or affinity, values for a large number of drugs and drug candidates at an expanding number of G-protein coupled receptors, ion channels, transporters and enzymes. The query interface is designed to let you search by any field, or combination of them to refine your search criteria. The flexible user interface also provides for customized data mining. The database is regularly updated. If you know of Ki data you would like to add, you can select Direct Ki Entry at the grey panel. If you would like, however, your own data (published or not) added, Send them a Reference at the grey panel, or send an email to Dr. Bryan Roth or Estela Lopez. Most common targets: 5-HT2A, DOPAMINE D1, DOPAMINE D2, 5-HT2C, 5-HT1A, Cholinergic, muscarinic M1, 5-HT Transporter, HISTAMINE H1, 5-HT2B, OPIOID Mu, 5-HT6, adrenergic Beta2, 5-HT7, OPIATE Delta, adrenergic Alpha1A, OPIOID Kappa, 5-HT3, m-AChR, adrenergic Beta1, adrenergic Alpha2A, 5-HT1, Acetylcholinesterase, AChE, Thromboxane A2, n-AChR, Opiate non-selective, CANNABINOID CB1, HERG, Dopamine, cocaine site, adrenergic Alpha2C, M3, Norepinephrine Uptake, Monoamine Oxidase A, Monoamine Oxidase B, 5-HT4, adrenergic Alpha1, 5-HT1E, B1 BRADYKININ, 5-HT2, 5-HT2C-INI, DOPAMINE D4, ANGIOTENSIN AT1, Neurokinin NK1, HISTAMINE H3, Sigma-1, VIP, Dopamine2-like, metabotropic glutamate 5, 5-HT2c VGL, Carbonic Anhydrase Isozymes, CA I, DOPAMINE D2 Long, adrenergic Alpha2, adrenergic Alpha2B, adrenergic Alpha2D, GABA A alpha1, CANNABINOID CB2, adrenergic Alpha1B, 5-HT5a, Melatonin, HISTAMINE H4, NMDA, 5-HT4a, Glucocorticoid, Interleukin 1-beta, Sodium Channel, Benzodiazepine central, Cholinergic, muscarinic M5, Neuropeptide Y1, GABA A alpha5, Galanin R2, Neurokinin NK3, 5-HT1B, M2, DOPAMINE D3, Angiotensin, Dopamine1-like, Neurokinin NK2, adrenergic Beta, Dopamine D1 high, Dopamine D1A, MAP kinase, ADENOSINE A2a, 5-HT7b, Nitrogen oxide synthase - neuronal, Sigma-2, CDK2, Neurotensin 2, DOPAMINE

D2 Short, Multidrug Resistance Transporter MDR 1, GABA A Benzodiazepine, VEGF-R2, OPIATE Mu 2, Angiotensin II AT1, HISTAMINE H2, Angiotensin-converting enzyme, ACE, Sigma, beta-amyloid, ADENOSINE, ADENOSINE A2B, Adrenaline, Neurotensin 1

**Abbreviations:** Ki DB

**Synonyms:** Ki Database, PDSP Ki Database

**Resource Type:** data or information resource, data repository, database, service resource, storage service resource

**Keywords:** gpcr, ki, 5-ht transporter, 5-ht2a, dopamine d2, dopamine d1, 5-ht1a, m1, dopamine transporter, opiate mu, histamine h1, adrenergic alpha1, 5-ht7, m2, 5-ht2c, cannabinoid cb1, adrenergic alpha2a, net, 5-ht3, 5-ht2b, adrenergic alpha1a, adrenergic beta1

**Funding:** NIMH ;  
Heffter Research Institute

**Availability:** THIS RESOURCE IS NO LONGER IN SERVICE

**Resource Name:** Psychoactive Drug Screening Program Ki Database

**Resource ID:** SCR\_003281

**Alternate IDs:** nif-0000-01866

**Record Creation Time:** 20220129T080218+0000

**Record Last Update:** 20260821T193657+0000

---

## Ratings and Alerts

No rating or validation information has been found for Psychoactive Drug Screening Program Ki Database.

No alerts have been found for Psychoactive Drug Screening Program Ki Database.

---

## Data and Source Information

**Source:** [SciCrunch Registry](#)

---

## Usage and Citation Metrics

We found 19 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [ASWG](#) .

Zhou JJ, et al. (2020) Group III metabotropic glutamate receptors regulate hypothalamic presympathetic neurons through opposing presynaptic and postsynaptic actions in hypertension. *Neuropharmacology*, 174, 108159.

- Jahangard L, et al. (2017) Children with ADHD and symptoms of oppositional defiant disorder improved in behavior when treated with methylphenidate and adjuvant risperidone, though weight gain was also observed - Results from a randomized, double-blind, placebo-controlled clinical trial. *Psychiatry research*, 251, 182.
- Watts SW, et al. (2015) 5-HT is a potent relaxant in rat superior mesenteric veins. *Pharmacology research & perspectives*, 3(1), e00103.
- Gurevich EV, et al. (2015) Beyond traditional pharmacology: new tools and approaches. *British journal of pharmacology*, 172(13), 3229.
- Elgoyhen AB, et al. (2014) Identifying tinnitus-related genes based on a side-effect network analysis. *CPT: pharmacometrics & systems pharmacology*, 3(1), e97.
- Drake RA, et al. (2014) The degree of acute descending control of spinal nociception in an area of primary hyperalgesia is dependent on the peripheral domain of afferent input. *The Journal of physiology*, 592(16), 3611.
- Nakayama H, et al. (2014) Two cases of mild serotonin toxicity via 5-hydroxytryptamine 1A receptor stimulation. *Neuropsychiatric disease and treatment*, 10, 283.
- Ferrie AM, et al. (2014) Divergent label-free cell phenotypic pharmacology of ligands at the overexpressed  $\alpha$ -adrenergic receptors. *Scientific reports*, 4, 3828.
- Rosenthaler S, et al. (2014) Differences in receptor binding affinity of several phytocannabinoids do not explain their effects on neural cell cultures. *Neurotoxicology and teratology*, 46, 49.
- López-Muñoz F, et al. (2013) Active metabolites as antidepressant drugs: the role of norquetiapine in the mechanism of action of quetiapine in the treatment of mood disorders. *Frontiers in psychiatry*, 4, 102.
- Kim K, et al. (2012) Neuroimmunological mechanism of pruritus in atopic dermatitis focused on the role of serotonin. *Biomolecules & therapeutics*, 20(6), 506.
- Wu H, et al. (2012) Structure of the human  $\mu$ -opioid receptor in complex with JDTic. *Nature*, 485(7398), 327.
- McEvoy J, et al. (2011) Coexpression of normally incompatible developmental pathways in retinoblastoma genesis. *Cancer cell*, 20(2), 260.
- Capuano B, et al. (2010) JL13 has clozapine-like actions on thermoregulatory cutaneous blood flow in rats: Involvement of serotonin 5-HT<sub>1A</sub> and 5-HT<sub>2A</sub> receptor mechanisms. *Progress in neuro-psychopharmacology & biological psychiatry*, 34(1), 136.
- Harmar AJ, et al. (2009) IUPHAR-DB: the IUPHAR database of G protein-coupled receptors and ion channels. *Nucleic acids research*, 37(Database issue), D680.
- Kim K, et al. (2009) A novel flow cytometric high throughput assay for a systematic study on molecular mechanisms underlying T cell receptor-mediated integrin activation. *PloS one*, 4(6), e6044.

Beig MI, et al. (2009) Blockade of 5-HT<sub>2A</sub> receptors suppresses hyperthermic but not cardiovascular responses to psychosocial stress in rats. *Neuroscience*, 159(3), 1185.

Gillman PK, et al. (2007) Tricyclic antidepressant pharmacology and therapeutic drug interactions updated. *British journal of pharmacology*, 151(6), 737.

Zhu H, et al. (2007) Expression and distribution of all dopamine receptor subtypes (D(1)-D(5)) in the mouse lumbar spinal cord: a real-time polymerase chain reaction and non-autoradiographic in situ hybridization study. *Neuroscience*, 149(4), 885.